The U.S. Department of Health and Human Services (HHS) announced on Wednesday that it is sponsoring a new broad spectrum antibiotic that could become the first of its kind to treat specific Gram-negative and Gram-positive infections.
The broad spectrum antibiotic is being looked at as a treatment for tularemia, a bioterrorism threat, and will undergo the last steps in development with support from the HHS office of the assistant secretary for preparedness and response (ASPR).
The sponsorship covers an 18-month, $20 million agreement between ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and Basilea Pharmaceutica International, Ltd. The company will conduct Phase 3 clinical studies of the antibiotic, Ceftobiprole, in treating both Gram-negative and Gram-positive infections.
“HHS is working aggressively to address the nation’s needs in public health emergencies,” Richard Hatchett, acting director of BARDA, said. “Those needs include treatments for antibiotic-resistant bacteria and to strengthen our defense against bioterror threats; by identifying a number of products that can address both needs, BARDA’s biodefense investments will yield important public health dividends.”
The treatment could be commercially available as a medical countermeasure or used in a bioterrorism emergency, pending FDA approval.
Thanks to work by Raytheon, an advanced new ground system for space-based missile warning recently…
According to the latest Elder Fraud Report from the Federal Bureau of Investigation (FBI), 2023…
Following the deaths of four police officers while executing an arrest warrant in North Carolina…
As a way to crackdown on human trafficking, two U.S. representatives recently introduced the Exposing…
A Department of Defense (DoD) 2040 Task Force (D2T) challenge on talent management innovation drew…
For the first time since its creation in 2004, the Transportation Security Administration’s (TSA) Flight…
This website uses cookies.